Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03808103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 15, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Sep 30, 2024 to Jun 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v10
  2. Study sites: 1 to 2
    • Collaborators: 1 to 2
    v9
  3. Primary and study completion dates: Sep 30, 2023 to Sep 30, 2024v8
  4. Primary completion date: Aug 2022 to Sep 30, 2023
    • Study completion date: Sep 2023 to Sep 30, 2023
    v7
  5. Primary completion date: Dec 2022 to Aug 2022
    • Study completion date: Jun 2023 to Sep 2023
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary completion date: Dec 2020 to Dec 2022
    • Study completion date: Jun 2021 to Jun 2023
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Start date changed from estimate of Mar 2019 to May 1, 2019v3
  4. Start date: Jan 2019 to Mar 2019v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the safety of oral administration of EcoActive to patients with inactive Crohn's disease and how it affects the levels of AIEC in stool.
Trial Details
NCT Number NCT03808103
Lead Sponsor Intralytix, Inc.
Collaborators: Icahn School of Medicine at Mount Sinai, Johns Hopkins University
Conditions
(from sponsor)		 Crohn Disease
Related terms Crohn Disease
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov